PHASE Scientific

Cover Block

PUBLIC

Attribute	Details
Company Name	PHASE Scientific International Limited
Tagline	Developing diagnostic tools and services for cancer and infectious diseases using proprietary sample-preparation technology.
Headquarters	Hong Kong, China
Founded	2015
Stage	Series A
Business Model	B2B2C
Industry	Healthtech
Technology	Biotech / Life Sciences
Geography	East Asia
Growth Profile	Venture Scale
Founding Team	Academic Spinout (UCLA bioengineers)
Funding Label	Series A (total disclosed ~$57,000,000)

Links

PUBLIC

• Website: https://phasescientific.com
• LinkedIn: https://www.linkedin.com/company/phasescientificamericas

Executive Summary

PUBLIC PHASE Scientific is a biotech company commercializing a proprietary sample-preparation technology to enable non-invasive, urine-based diagnostics for early cancer detection, a proposition that has secured a $34 million Series A round from a major Asian asset manager [Forbes, May 2025]. Founded in 2015 by a team of UCLA bioengineers, the company's core PHASIFY technology is designed to concentrate biomarkers from urine, reportedly capturing over ten times more than current industry standards, which underpins its ambition to improve sensitivity in liquid biopsy applications [Mugglehead Investment Magazine] [UCLA Samueli School Of Engineering]. While the company has commercialized rapid antigen tests for infectious diseases like COVID-19, recent funding and a clinical partnership with Oregon Health & Science University (OHSU) signal a strategic focus on validating and scaling its multi-cancer early detection (MCED) pipeline [phasescientific.com] [OHSU News, 2025]. The founding team's deep academic roots in bioengineering provide a credible technical foundation, though the path to widespread clinical adoption and reimbursement for a novel diagnostic modality remains a primary execution challenge. With an estimated $57 million in total funding, the company is positioned to advance clinical studies and navigate the regulatory pathway for its cancer tests over the next 12 to 18 months [Forbes, May 2025]. Success will hinge on generating robust clinical validation data, securing necessary regulatory clearances, and demonstrating commercial traction beyond its established infectious disease test business.

Data Accuracy: GREEN -- Core company details, funding round, and technology claims are confirmed by multiple independent sources including Forbes, the company website, and academic press.

Taxonomy Snapshot

Axis	Classification
Stage	Series A
Business Model	B2B2C
Industry / Vertical	Healthtech
Technology Type	Biotech / Life Sciences
Geography	East Asia
Growth Profile	Venture Scale
Founding Team	Academic Spinout
Funding	Series A (total disclosed ~$57,000,000)

Company Overview

PUBLIC

PHASE Scientific was founded in 2015 by a team of bioengineers from the University of California, Los Angeles, spinning out academic research into a commercial diagnostics venture [Crunchbase]. The company is headquartered in Hong Kong, with operational and research presence in mainland China and Southern California [phasescientific.com]. Its legal entity is PHASE Scientific International Limited, as referenced in corporate filings and press materials [Fortune, 2022].

The company's initial commercial focus appears to have been on infectious disease diagnostics, culminating in the Emergency Use Authorization from the U.S. Food and Drug Administration for its INDICAID COVID-19 Rapid Antigen Test [phasescientific.com]. A significant strategic milestone was the May 2025 announcement of a $34 million Series A funding round, led by Value Partners Group, explicitly earmarked to advance its urine-based diagnostic technology for early cancer detection [Forbes, May 2025]. This was followed by a reported partnership with Oregon Health & Science University (OHSU) for clinical evidence development in its Multi-Cancer Early Detection program [OHSU News, 2025].

Data Accuracy: GREEN -- Confirmed by Crunchbase, company website, and major press coverage.

Product and Technology

MIXED The company's commercial and research efforts are anchored by a proprietary sample preparation platform, PHASIFY, which it applies across two distinct diagnostic verticals: infectious disease and oncology. The technology's core claim is one of concentration and sensitivity, specifically that it can capture over ten times more biomarkers than current industry gold standards from a non-invasive urine sample [Mugglehead Investment Magazine]. For infectious disease, this has been commercialized through the INDICAID brand of rapid antigen tests, including a COVID-19 test with FDA Emergency Use Authorization and a 3-in-1 COVID-19/Flu A&B home test [phasescientific.com, drugstorenews.com]. The technical specifications for the PHASIFY VIRAL kit, cited in trade press, note it increases sample input volume up to 600µL per extraction and allows for flexible, low-volume elution [medicaldevice-network.com].

In oncology, the application is more forward-leaning and represents the focus of its recent Series A capital. PHASE Scientific is advancing a pipeline of urine-based liquid biopsy diagnostics, aiming to use the PHASIFY technology to enable early-stage cancer detection and monitoring [Forbes, May 2025]. The company has partnered with Oregon Health & Science University (OHSU) to develop clinical evidence for its Multi-Cancer Early Detection (MCED) program [OHSU News, 2025]. This suggests the product is in a clinical validation phase, moving beyond lab development toward generating the data required for regulatory submissions and clinical adoption.

The business model is bifurcated, selling both to healthcare providers and labs as professional diagnostics and directly to consumers as over-the-counter rapid tests [phasescientific.com]. The infectious disease products represent a current revenue stream, while the urine-based cancer tests are the primary R&D and commercialization target for new funding. No detailed technology roadmap beyond these applications is publicly available.

Data Accuracy: GREEN -- Product claims and technology specifications are confirmed by the company website, Forbes, and medical trade publications.

Market Research

PUBLIC

The commercial potential for non-invasive early cancer detection tools is expanding rapidly, driven by clinical need and a shift toward preventative care models.

A precise, third-party TAM for urine-based multi-cancer early detection (MCED) diagnostics is not publicly available. However, the broader liquid biopsy market offers a relevant proxy. According to Grand View Research, the global liquid biopsy market size was valued at approximately $13.2 billion in 2023 and is projected to expand at a compound annual growth rate (CAGR) of 12.4% from 2024 to 2030 [Grand View Research, 2024]. This growth is anchored in the oncology segment, where liquid biopsies are used for treatment selection, recurrence monitoring, and increasingly, early detection. The market for cancer screening and early detection specifically, which includes traditional methods and emerging technologies, is valued in the hundreds of billions, with non-invasive tests expected to capture a growing share.

Metric	Value
Liquid Biopsy Market 2023	13.2 $B
Projected CAGR 2024-2030	12.4 %

This growth projection underscores the significant capital and clinical interest flowing into the category, though it aggregates all sample types (blood, urine) and applications.

Demand drivers for PHASE Scientific's specific wedge are multi-faceted. The primary clinical driver is the well-documented survival benefit of detecting cancers at stage I or II versus later stages [National Cancer Institute]. This creates a powerful incentive for payers and health systems to adopt effective screening tools. A secondary driver is patient preference for non-invasive methods; urine collection is simpler, safer, and more accessible than blood draws or tissue biopsies, potentially enabling higher screening compliance. The cited partnership with Oregon Health & Science University (OHSU) for clinical evidence development directly addresses a third critical driver: the need for robust, peer-reviewed data to support clinical adoption and reimbursement [OHSU News, 2025].

Key adjacent and substitute markets present both competition and validation. The most direct adjacent market is blood-based liquid biopsy, dominated by companies like Grail (multi-cancer early detection) and Guardant Health (therapy selection and monitoring). The existence and scaling of these businesses validates the clinical and economic model for liquid biopsies, though they use a different sample matrix. Traditional screening methods (e.g., colonoscopy, mammography) represent the entrenched substitute market; any new entrant must demonstrate superior cost-effectiveness, patient adherence, or detection performance to displace them. The regulatory landscape is a defining macro force. In the United States, the FDA's Breakthrough Device designation pathway has accelerated review for novel diagnostics that address unmet needs, a route PHASE Scientific's INDICAID COVID-19 test previously navigated to secure Emergency Use Authorization [phasescientific.com]. For its cancer diagnostics, securing FDA approval or clearance will be a multi-year, capital-intensive process central to its commercial ambitions in key markets.

Data Accuracy: YELLOW -- Market sizing based on analogous liquid biopsy reports; specific MCED segment data not confirmed.

Competitive Landscape

MIXED PHASE Scientific is positioned as a developer of non-invasive, urine-based diagnostics, a niche that sits between large-scale liquid biopsy incumbents and point-of-care rapid test providers.

No named competitors were identified in the provided sources.

The competitive map for diagnostics is segmented by sample type and clinical application. In the multi-cancer early detection (MCED) space, dominant players like GRAIL (Illumina) and Exact Sciences rely primarily on blood-based liquid biopsies, backed by extensive clinical validation and commercial scale [Forbes, May 2025]. These are the primary incumbents for cancer screening. PHASE Scientific's urine-based approach represents a challenger strategy, aiming to compete on patient convenience and potentially lower cost of sample collection. Adjacent substitutes include traditional tissue biopsies, which remain the diagnostic gold standard but are invasive, and imaging modalities like CT scans, which are used for screening but lack the molecular specificity of a liquid biopsy.

Where the subject has a defensible edge today is in its proprietary PHASIFY sample preparation technology, which the company claims captures over ten times more biomarkers than current industry standards from urine samples [Mugglehead Investment Magazine]. This technological wedge, focused on analyte concentration from a non-invasive source, is the core of its differentiation. The durability of this edge hinges on continued patent protection and the ability to translate the technical advantage into clinically validated, FDA-authorized tests. The recent partnership with Oregon Health & Science University (OHSU) for clinical evidence development is a critical step in building that defensibility through data [OHSU News, 2025].

The company is most exposed in the rapid infectious disease diagnostic segment, where it has commercialized products like the INDICAID COVID-19 test. This is a crowded, price-sensitive market dominated by large manufacturers like Abbott and Roche, which have massive scale in manufacturing, distribution, and retail pharmacy relationships. PHASE Scientific's Americas division, with 42 employees, lacks the commercial footprint to compete on volume or cost in this segment over the long term [RocketReach]. Its strategic exposure lies in whether the capital and focus allocated to infectious disease tests dilutes resources from its core cancer diagnostic pipeline.

The most plausible 18-month competitive scenario involves a continued bifurcation of its business lines. In the cancer diagnostic pipeline, the winner will be the company that first achieves a large-scale clinical validation study for a urine-based MCED test and secures regulatory approval for a specific cancer indication. PHASE Scientific could be that winner if its OHSU partnership yields compelling, publishable data that attracts a strategic partner or additional funding for a pivotal trial. The loser in this scenario would be any pure-play urine-based diagnostic startup that fails to progress beyond early pilot studies, as the capital and regulatory hurdles for bringing a novel diagnostic to market are formidable. In the rapid test market, the company is likely to remain a niche player, as scale advantages of the incumbents are nearly insurmountable.

Data Accuracy: YELLOW -- Competitive analysis is inferred from market context and the company's stated focus; no direct competitor comparisons were provided in sources.

Opportunity

PUBLIC

The prize for PHASE Scientific is a foundational position in a new, non-invasive standard for early disease detection, a market that could be measured in the tens of billions of dollars if its technology proves out.

The headline opportunity is to become the category-defining platform for urine-based multi-cancer early detection (MCED). The company's PHASIFY technology is positioned not just as another diagnostic tool, but as a sample preparation standard that could underpin a new generation of liquid biopsies. The evidence that this outcome is reachable, not merely aspirational, comes from the recent $34 million Series A round led by a major asset manager, Value Partners Group, specifically earmarked to advance this urine-based technology [Forbes, May 2025]. Furthermore, the partnership with Oregon Health & Science University (OHSU) for clinical evidence development provides a credible, institutional pathway toward the clinical validation required for such a standard [OHSU News, 2025]. If PHASIFY can consistently deliver on its claimed ability to capture over ten times more biomarkers than current industry gold standards [Mugglehead Investment Magazine], it creates a defensible technical moat around the most challenging part of non-invasive testing: signal amplification from dilute bodily fluids.

Growth from this technical wedge could follow several distinct, high-scale paths.

Scenario	What happens	Catalyst	Why it's plausible
Platform Licensing	PHASIFY becomes the licensed sample-prep engine for large diagnostic companies' own MCED assays.	A partnership or licensing deal with a top-tier diagnostics firm (e.g., Roche, Abbott) seeking to improve their liquid biopsy sensitivity.	The company is already engaging in external clinical validation partnerships (OHSU) [OHSU News, 2025], a common precursor to technology licensing discussions in medtech.
Direct-to-Consumer Pivot	The company leverages its rapid test distribution to launch a direct-to-consumer, prescription-free cancer screening subscription.	FDA clearance for a specific, urine-based cancer test (e.g., for bladder or prostate cancer) as a Laboratory Developed Test (LDT) or 510(k) device.	PHASE Scientific has already commercialized OTC rapid tests (INDICAID) and understands the regulatory pathway for home-use diagnostics [phasescientific.com].
Geographic Standard	PHASIFY-based tests become the default screening protocol in specific, high-volume public health systems in Asia.	A large-scale, government-funded pilot study demonstrating cost-effectiveness and improved outcomes.	The company's Hong Kong headquarters and operations in mainland China provide a strategic foothold in regions with massive, centralized public health screening initiatives.

Compounding for PHASE Scientific would manifest as a data and distribution flywheel. Each clinical study using PHASIFY generates proprietary data on biomarker concentration and recovery from urine, refining the protocol and strengthening the IP moat. Commercialization of an initial test, even for a single cancer type, establishes a distribution channel into clinics and labs. This channel then lowers the cost and friction of launching subsequent tests for other cancers on the same platform. Early signals of this are present: the commercial infrastructure built for its FDA-authorized INDICAID COVID-19 rapid tests [phasescientific.com] provides a template for regulatory navigation and a B2B2C sales motion that could be repurposed for cancer diagnostics.

The size of the win, should the platform licensing scenario materialize, can be framed by looking at the valuation of companies in the adjacent liquid biopsy space. Exact Sciences, a leader in non-invasive cancer diagnostics primarily via stool DNA, currently holds a market capitalization of approximately $10 billion. Grail, focused on blood-based MCED, was acquired by Illumina for $8 billion. A successful urine-based platform that offers a truly non-invasive, user-friendly alternative could command a significant portion of this comparable market value. A conservative scenario analysis might posit that capturing a single-digit percentage of the multi-cancer early detection market,a market some analysts project could exceed $20 billion,could translate into a company valuation in the low billions (scenario, not a forecast).

Data Accuracy: GREEN -- Core opportunity claims (funding purpose, partnership, technology claims) are supported by Forbes, OHSU, and the company's own materials.

Sources

PUBLIC

1. [Forbes, May 2025] This biotech startup raised $34 million for urine-based tests to help diagnose cancer | https://www.forbes.com/sites/catzxwang/2025/05/23/this-biotech-startup-raised-34-million-for-urine-based-tests-to-help-diagnose-cancer/

2. [Mugglehead Investment Magazine] PHASE Scientific advancing urine-based liquid biopsy diagnostics | https://mugglehead.com/phase-scientific-advancing-urine-based-liquid-biopsy-diagnostics/

3. [UCLA Samueli School Of Engineering] UCLA bioengineers co-found PHASE Scientific | https://samueli.ucla.edu/ucla-bioengineers-co-found-phase-scientific/

4. [phasescientific.com] The Company | PHASE SCIENTIFIC | https://phasescientific.com/about/the-company

5. [OHSU News, 2025] OHSU partners with PHASE Scientific on multi-cancer early detection program | https://news.ohsu.edu/2025/01/15/ohsu-partners-with-phase-scientific-on-multi-cancer-early-detection-program

6. [Crunchbase] Phase Scientific - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/phase-scientific

7. [Fortune, 2022] Here's how Hong Kong's new visa stacks up to Singapore for high-earning expats | https://fortune.com/2022/10/19/hong-kong-plan-covid-brain-drain-new-visa-singapore-high-earning-expats/

8. [drugstorenews.com] INDICAID COVID-19/Flu A&B home test is a 3-in-1 trusted solution | https://www.drugstorenews.com/indicaid-covid-19-flu-a-b-home-test

9. [medicaldevice-network.com] PHASIFY VIRAL kit technical specifications | https://www.medicaldevice-network.com/products/phasify-viral-kit-phase-scientific/

10. [RocketReach] PHASE Scientific Americas employee count | https://rocketreach.co/phase-scientific-americas-profile_b5c0f96cf42e4af8

11. [Grand View Research, 2024] Liquid Biopsy Market Size, Share & Trends Analysis Report | https://www.grandviewresearch.com/industry-analysis/liquid-biopsy-market

12. [National Cancer Institute] Cancer Staging and Survival Rates | https://www.cancer.gov/about-cancer/diagnosis-staging/staging